Cookies


ESHRE ® uses cookies to improve your browsing experience on its website, as defined in the Cookie Policy (as updated on 18/03/2024). Strictly necessary cookies are necessary for the proper functioning of the Website – therefore, you cannot refuse them. Other, non-strictly necessary cookies are only placed if you consent to their use. Read more about it in our Cookie Policy. Do you agree with our use of non-strictly necessary cookies?
Manage my cookie preferences

Professor Dr Panagiotis Drakopoulous

Drakopoulos

Panagiotis Drakopoulos MD,Msc, Ph.D. is visiting Professor and senior fertility specialist, working at the Centre for Reproductive Medicine (UZ Brussel) in Belgium. His current research activities are focused on reproductive endocrinology, poor ovarian responders and strategies to improve their outcome.

Main publications:

Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.

Drakopoulos P, Vuong TNL, Ho NAV, Vaiarelli A, Ho MT, Blockeel C, Camus M, Lam AT, van de Vijver A, Humaidan P, Tournaye H, Polyzos NP.

The effect of serum vitamin D levels on ovarian reserve markers: a prospective cross-sectional study.
Drakopoulos P, van de Vijver A, Schutyser V, Milatovic S, Anckaert E, Schiettecatte J, Blockeel C, Camus M, Tournaye H, Polyzos NP.

Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, Polyzos NP.

Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women.
Polyzos NP, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, Bosch E, Garcia-Velasco J.

Serum Anti-Müllerian Hormone Is Significantly Altered by Downregulation With Daily Gonadotropin-Releasing Hormone Agonist: A Prospective Cohort Study.
Drakopoulos P, van de Vijver A, Parra J, Anckaert E, Schiettecatte J, Blockeel C, Hund M, Verhagen-Kamerbeek WDJ, He Y, Tournaye H, Polyzos NP.